{"id":169,"date":"2026-05-30T13:14:13","date_gmt":"2026-05-30T13:14:13","guid":{"rendered":"https:\/\/officemovingamerica.com\/?p=169"},"modified":"2026-05-30T13:14:13","modified_gmt":"2026-05-30T13:14:13","slug":"incyte-blood-cancer-drug-combo-reduces-disease-progression-risk-but-with-high-side-effect-rate","status":"publish","type":"post","link":"https:\/\/officemovingamerica.com\/?p=169","title":{"rendered":"Incyte Blood Cancer Drug Combo Reduces Disease-Progression Risk but With High Side-Effect Rate"},"content":{"rendered":"<div>\n<div>\n<p>By Christy Santhosh<\/p>\n<\/div>\n<div>\n<p>May 30 (Reuters) &#8211; Incyte&#8217;s Monjuvi as part of a \u2060multi-drug \u2060regimen that includes a chemotherapy \u2060standard of care for an aggressive form of non-Hodgkin lymphoma reduced the risk \u200bof disease progression, relapse or death by 25% compared to the standard alone, but with a higher rate of study \u200cdropouts due to side effects.<\/p>\n<p>Read more <a href=\"https:\/\/officemovingamerica.com\/?p=168\">New Jersey State Police Assert Control Outside Migrant Detention Center<\/a><\/p>\n<\/div>\n<div>\n<div><\/div>\n<\/div>\n<div>\n<p>The company, \u200cwhich first announced the data in January, said it would have overall survival data for the drug \u2060combination at a \u2060later date. Pablo Cagnoni, Incyte&#8217;s research chief, said the survival analysis was &#8220;early&#8221; \u200bbut showed a clear trend toward improvement.\u00a0<\/p>\n<\/div>\n<div>\n<div><\/div>\n<\/div>\n<div>\n<p>The trial tested a combination of Monjuvi, Bristol Myers Squibb&#8217;s blood cancer drug Revlimid and R-CHOP &#8211; a standard multi-chemotherapy regimen &#8211; against R-CHOP alone, in some 900 patients with newly diagnosed diffuse large B-cell lymphoma, \u200bor DLBCL, the most common type of non-Hodgkin lymphoma.<\/p>\n<\/div>\n<div>\n<p>Analysts and investors were anxious for more side effect \u2060and \u2060discontinuation data from the intensive \u2060multi-drug therapy.<\/p>\n<\/div>\n<div>\n<p>Severe adverse \u200bevents were more common for those who received the Monjuvi combo at nearly 87% versus 76% of \u200bpatients who just got R-CHOP, \u2060which involves five medicines.<\/p>\n<\/div>\n<div>\n<p>Discontinuations due to treatment-related adverse events were also higher at 25.7%, compared with 18% for standard care. Deaths listed as due to adverse events were 6% in the Incyte drug group, compared with 3.8% for standard care.<\/p>\n<\/div>\n<div>\n<p>The overall death rate, however, was lower for the Incyte\/ Bristol Myers\/R-CHOP combination at 18.5%, compared \u2060to 21.7% for R-CHOP.<\/p>\n<p>Read more <a href=\"https:\/\/officemovingamerica.com\/?p=166\">Social Media Companies to Pay $27 Million to Settle Kentucky School District\u2019s Lawsuit, Records Show<\/a><\/p>\n<\/div>\n<div>\n<p>&#8220;Sometimes when you add another drug, you obviously see a little bit \u2060more side effects, which is why it&#8217;s so important to report the survival data, because all of this gets integrated into survival,&#8221; said Incyte&#8217;s Cagnoni.<\/p>\n<\/div>\n<div><\/div>\n<div>\n<p>The detailed results were presented at the American Society of Clinical Oncology meeting in Chicago.<\/p>\n<\/div>\n<div>\n<p>Cagnoni said more than 50% of the high-risk patient population that still receives R-CHOP as treatment could be eligible for the new regimen as a first-line, or initial, therapy as soon as it gets approval.<\/p>\n<\/div>\n<div>\n<p>About 18,000 to 25,000 people in the U.S. are diagnosed with the disease each year, according to government data.<\/p>\n<\/div>\n<div>\n<p>Monjuvi, known chemically as tafasitamab, received accelerated \u2060U.S. approval in combination with Revlimid for patients whose disease has returned or did not respond to earlier treatment, and those who are not eligible for stem cell transplant.<\/p>\n<\/div>\n<div>\n<p>Cagnoni said the company plans to seek expanded approval in the U.S. and Europe for the combo therapy as an \u200binitial treatment for newly diagnosed patients.<\/p>\n<p>Read more <a href=\"https:\/\/officemovingamerica.com\/?p=164\">US Investigates Vietnam\u2019s Intellectual Property Practices<\/a><\/p>\n<\/div>\n<div>\n<p>&#8220;This doubles the potential eligible population,&#8221; Cagnoni said.<\/p>\n<\/div>\n<div><\/div>\n<div>\n<p>(Reporting \u200bby Christy Santhosh in Bengaluru; Editing by Bill Berkrot)<\/p>\n<\/div>\n<div>\n<p><b>Copyright 2026 Thomson Reuters<\/b>.<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[66],"tags":[127,8,60],"class_list":["post-169","post","type-post","status-publish","format-standard","hentry","category-top-news","tag-cancer","tag-sign-in-to-manage-your-newsletters","tag-united-states"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Incyte Blood Cancer Drug Combo Reduces Disease-Progression Risk but With High Side-Effect Rate - Office Moving America<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/officemovingamerica.com\/?p=169\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Incyte Blood Cancer Drug Combo Reduces Disease-Progression Risk but With High Side-Effect Rate - Office Moving America\" \/>\n<meta property=\"og:description\" content=\"US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/officemovingamerica.com\/?p=169\" \/>\n<meta property=\"og:site_name\" content=\"Office Moving America\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-30T13:14:13+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=169#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=169\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/#\\\/schema\\\/person\\\/953f33efe585ac76cdf8428d434d3061\"},\"headline\":\"Incyte Blood Cancer Drug Combo Reduces Disease-Progression Risk but With High Side-Effect Rate\",\"datePublished\":\"2026-05-30T13:14:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=169\"},\"wordCount\":481,\"commentCount\":0,\"keywords\":[\"cancer\",\"Sign in to manage your newsletters \u00bb\",\"United States\"],\"articleSection\":[\"Top News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/officemovingamerica.com\\\/?p=169#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=169\",\"url\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=169\",\"name\":\"Incyte Blood Cancer Drug Combo Reduces Disease-Progression Risk but With High Side-Effect Rate - Office Moving America\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/#website\"},\"datePublished\":\"2026-05-30T13:14:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/#\\\/schema\\\/person\\\/953f33efe585ac76cdf8428d434d3061\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=169#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/officemovingamerica.com\\\/?p=169\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/?p=169#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/officemovingamerica.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Incyte Blood Cancer Drug Combo Reduces Disease-Progression Risk but With High Side-Effect Rate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/#website\",\"url\":\"https:\\\/\\\/officemovingamerica.com\\\/\",\"name\":\"Office Moving America\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/officemovingamerica.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/officemovingamerica.com\\\/#\\\/schema\\\/person\\\/953f33efe585ac76cdf8428d434d3061\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\\\/\\\/officemovingamerica.com\"],\"url\":\"https:\\\/\\\/officemovingamerica.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Incyte Blood Cancer Drug Combo Reduces Disease-Progression Risk but With High Side-Effect Rate - Office Moving America","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/officemovingamerica.com\/?p=169","og_locale":"en_US","og_type":"article","og_title":"Incyte Blood Cancer Drug Combo Reduces Disease-Progression Risk but With High Side-Effect Rate - Office Moving America","og_description":"US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.","og_url":"https:\/\/officemovingamerica.com\/?p=169","og_site_name":"Office Moving America","article_published_time":"2026-05-30T13:14:13+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/officemovingamerica.com\/?p=169#article","isPartOf":{"@id":"https:\/\/officemovingamerica.com\/?p=169"},"author":{"name":"admin","@id":"https:\/\/officemovingamerica.com\/#\/schema\/person\/953f33efe585ac76cdf8428d434d3061"},"headline":"Incyte Blood Cancer Drug Combo Reduces Disease-Progression Risk but With High Side-Effect Rate","datePublished":"2026-05-30T13:14:13+00:00","mainEntityOfPage":{"@id":"https:\/\/officemovingamerica.com\/?p=169"},"wordCount":481,"commentCount":0,"keywords":["cancer","Sign in to manage your newsletters \u00bb","United States"],"articleSection":["Top News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/officemovingamerica.com\/?p=169#respond"]}]},{"@type":"WebPage","@id":"https:\/\/officemovingamerica.com\/?p=169","url":"https:\/\/officemovingamerica.com\/?p=169","name":"Incyte Blood Cancer Drug Combo Reduces Disease-Progression Risk but With High Side-Effect Rate - Office Moving America","isPartOf":{"@id":"https:\/\/officemovingamerica.com\/#website"},"datePublished":"2026-05-30T13:14:13+00:00","author":{"@id":"https:\/\/officemovingamerica.com\/#\/schema\/person\/953f33efe585ac76cdf8428d434d3061"},"breadcrumb":{"@id":"https:\/\/officemovingamerica.com\/?p=169#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/officemovingamerica.com\/?p=169"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/officemovingamerica.com\/?p=169#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/officemovingamerica.com\/"},{"@type":"ListItem","position":2,"name":"Incyte Blood Cancer Drug Combo Reduces Disease-Progression Risk but With High Side-Effect Rate"}]},{"@type":"WebSite","@id":"https:\/\/officemovingamerica.com\/#website","url":"https:\/\/officemovingamerica.com\/","name":"Office Moving America","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/officemovingamerica.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/officemovingamerica.com\/#\/schema\/person\/953f33efe585ac76cdf8428d434d3061","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/officemovingamerica.com"],"url":"https:\/\/officemovingamerica.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=\/wp\/v2\/posts\/169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=169"}],"version-history":[{"count":0,"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=\/wp\/v2\/posts\/169\/revisions"}],"wp:attachment":[{"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/officemovingamerica.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}